What should the target serum glucose level be for a diabetic patient in the hospital?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For hospitalized diabetic patients, serum glucose targets should generally be maintained between 140-180 mg/dL (7.8-10.0 mmol/L). This range balances the risks of hypoglycemia with the benefits of glycemic control, as supported by the most recent guidelines from 2025 1. The recommendation to initiate insulin therapy for treatment of persistent hyperglycemia ≥180 mg/dL ($10.0 mmol/L) and target a glucose range of 140–180 mg/dL (7.8–10.0 mmol/L) for most critically ill individuals with hyperglycemia is based on the findings from the NICE-SUGAR trial and several meta-analyses 1.

Some key points to consider in managing serum glucose levels in hospitalized diabetic patients include:

  • More stringent glycemic goals, such as 110–140 mg/dL (6.1–7.8 mmol/L), may be appropriate for selected individuals, such as critically ill individuals undergoing cardiac surgery, if they can be achieved without significant hypoglycemia 1.
  • Less stringent targets may be needed for critically ill patients or those with severe comorbidities, with glucose concentrations between 180 mg/dL and 250 mg/dL (10–13.9 mmol/L) potentially being acceptable in certain situations 1.
  • Management typically involves basal-bolus insulin regimens, with blood glucose monitored before meals and at bedtime, and additional checks for symptoms of hypoglycemia or in critically ill patients.
  • Medication adjustments should be made gradually based on glucose patterns, with particular attention to preventing nocturnal hypoglycemia.

Overall, the goal is to balance the risks of hypoglycemia with the benefits of glycemic control, and to individualize treatment based on the specific needs and circumstances of each patient, as supported by the most recent and highest quality evidence 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Serum Glucose Targets for Diabetic Patients in the Hospital

  • The target serum glucose level for diabetic patients in the hospital varies depending on the patient's condition and the hospital setting 2, 3, 4.
  • For critically ill patients, the recommended serum glucose target is between 140 and 180 mg/dL 2, 3, 4.
  • In non-critically ill patients, the premeal serum glucose target is less than 140 mg/dL, and random serum glucose levels should be less than 180 mg/dL 4.
  • Some studies suggest that tighter glycemic control (i.e., 110-140 mg/dL) may be appropriate for certain patients, such as those with neurological or surgical conditions, if hypoglycemia can be properly avoided 3.
  • It is essential to avoid hypoglycemia, and insulin regimens should be reassessed if serum glucose levels fall to less than 100 mg/dL 4.

Glycemic Control Strategies

  • Intravenous (IV) insulin is the most appropriate treatment for critically ill patients, with a starting threshold no higher than 180 mg/dL 2, 4.
  • For non-critically ill patients, basal-bolus regimens with basal, prandial, and correction components are preferred for those with good nutritional intake, while a single dose of long-acting insulin plus correction insulin is preferred for patients with poor or no oral intake 2.
  • Scheduled subcutaneous insulin is the treatment of choice for hyperglycemia in non-critically ill patients, and the use of sliding-scale insulin is strongly discouraged 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of critically ill patients with diabetes.

World journal of diabetes, 2017

Research

Reexamining the evidence for inpatient glucose control: new recommendations for glycemic targets.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010

Related Questions

What dose of regular insulin is required for a blood glucose level of 452 milligrams per deciliter (mg/dL)?
What guidance is recommended for a 46-year-old patient with newly diagnosed type 2 diabetes mellitus, initiated on 750 mg of metformin (metformin hydrochloride), presenting with impaired fasting glucose (fasting blood glucose 174 mg/dL)?
What adjustments should be made to the insulin regimen and nutrition plan for a patient with poor PO intake and mucocitis post BMT, on Lantus (insulin glargine) 32 units, with an overnight blood glucose of 83 mg/dL?
What is the recommended inpatient management for severe hyperglycemia without Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS), including choice of basal-bolus insulin versus insulin infusion, starting dose for insulin-naïve patients, and monitoring parameters?
What is the second line of treatment for a 34-year-old patient with new onset type 2 diabetes mellitus, presenting with severe hyperglycemia and an elevated Hemoglobin A1c (HbA1c) level of 12%, who is already on metformin (metformin)?
What vitamin deficiencies are associated with Ulcerative Colitis (UC)?
What is the usual course of hypothyroidism exacerbated by Computed Tomography (CT) contrast?
What is the pathophysiology of Hypertensive Renal Disease (HRD) with Chronic Kidney Disease (CKD)?
Is Augmentin (amoxicillin-clavulanate) effective for treating otitis media?
What is the diagnosis and first line of treatment for a patient with hypercholesterolemia (elevated Total Cholesterol), hypertriglyceridemia (elevated Triglycerides), low High-Density Lipoprotein (HDL) Cholesterol, elevated Very-Low-Density Lipoprotein (VLDL) Cholesterol, and elevated Low-Density Lipoprotein (LDL) Cholesterol?
What is the diagnosis and management of heart failure with reduced ejection fraction (HFrEF) in patients with Giant Cell Myocarditis (GCM) or Giant Cell Disease (GCD) associated myocardial toxicity?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.